anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Variants in the RPGR are the leading cause of X-linked retinopathies (XLRPs). Further in-depth investigation is needed to understand the natural history.
METHODS: Review of all case records, molecular genetic testing results, best-corrected visual acuity (BCVA), retinal imaging data (including fundus autofluorescence imaging and optical coherence tomography (OCT)), static visual field (VF) assessments and full-field electroretinogram.
RESULTS: Genetic testing was conducted on 104 male patients from 89 family pedigrees, identifying 22 novel variants and 1 de novo variant. The initial symptoms appeared in 78.2% of patients at a median age of 5 years. BCVA declined at a mean rate of 0.02 (IQR, 0-0.04) logarithm of the minimum angle of resolution per year, with a gradual, non-linear decrease over the first 40 years. Autofluorescence imaging revealed macular atrophy at a median age of 36.1 (IQR, 29.9-43.2) years. Patients experienced blindness at a median age of 42.5 (IQR, 32.9-45.2) years according to WHO visual impairment categories. OCT analysis showed a mean ellipsoid zone narrowing rate of 23.3 (IQR, -1.04-22.29) µm/month, with an accelerated reduction in the first 40 years (p<0.01). The median age at which ERG no longer detected a waveform was 26.5 (IQR, 20.5-32.8) years. Comparison by variant location indicated faster progression in patients with exon 1-14 variants during the initial two decades, while those with ORF15 variants showed accelerated progression from the third decade.
CONCLUSIONS: We provide a foundation for determining the treatment window and an objective basis for evaluating the therapeutic efficacy of gene therapy for XLRP.
The POPSICLE study is a multi-centre, international research study that will investigate the prevalence, risk factors and consequences of chronic post-surgical pain (CPSP) in children 0-16 years undergoing the following common paediatric surgeries: laparoscopic appendicectomy, scrotal exploration, orchidopexy, hypospadias repair and circumcisions. CPSP as well as risk factors and their association with chronic pain, including parent and child anxiety, pre-existing pain, peri-operative pain experience and acute post-operative management, will be assessed through a series of longitudinal questionnaires at 6 timepoints from pre-surgery to 10-12 months post-surgery. Baseline measures will be completed pre-operatively and post-surgery measures of pain and function will be undertaken at Day 2, 3-4 weeks, 3-4 months and 10-12 months post-operatively.

Chronic pain has a significant effect on children's quality of life, negatively impacting their physical, emotional and social health as well as schooling. Additionally, adolescent chronic pain is associated with higher rates of depression, anxiety, feeling of helplessness and lack of autonomy compared to healthy children. Therefore, evidence-based knowledge from this research will inform perioperative practice minimising the risk of a child going on to develop chronic post-surgical pain. This will benefit the child, their family and the healthcare system by aiding in the formulation of practice guidelines to follow high risk children more closely to treat any potential persistent pain earlier to avoid the development of chronic pain.
Patients will receive a combination therapy of microneedling and minoxidil 5%. Minoxidil 5%, will be given twice a day for a total duration of 12 weeks. The microneedling treatment will be given every 4 weeks (week 0, week 4, week 8)for a total duration of 12 weeks.
Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
In order that they should reach optimum gastrulation size for incubation, average eggs laid by certain age flocks of geese of identical genotypem are treated as follows. Eggs with a max storage period of 7 days are treated at any time following the first day of laying. Eggs of geese in their first year are warmed for 12 hours and cooled for 5 hours. Conversely, milk eggs may be warmed for two separate periods of 5 hours, followed by 5 hours cooling each. In case of a necessary 25 days storing period prior to incubation, first warming occurs 1-3 days after laying with subsequent warmings every five days. During intervening eggs are stored at 10 deg.C, at 75-85 degs relative humidity and turned by 90 degs every four hours.
Cupric Chloride Injection, USP 0.4 mg/mL contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.)
31 The present invention relates to complex compounds of transition metals with emphasis on 99mTc and Re, which exhibit high blood-brain barrier permeability so that they may be used as diagnostic/therapeutic agents for CNS diseases. The novel compounds have the general structural formula where the M(CO)3+ tricarbonyl-metal core forms a complex with the cyclopentadienyl anion linked to heterocyclic moieties of the benzothiazole, benzimidazole and benzoxazole families. The blood-brain barrier permeability for three of the novel compounds with Μ = 99mTc ranges between 7.04 and 3.99 %ID/gr at 2 min post injection. Moreover, the novel compounds exhibit effective binding in vitro to β-amyloid fibrils as well as to amyloid plaques that characterize Alzheimer's disease, they inhibit the β-amyloid peptide induced cytotoxicity in cell cultures, and they drastically reduce the β-amyloid peptide induced ROS production also linked with Alzheimer's disease. Consequently, they have proven potential for application as diagnostic/therapeutic agents against Alzheimer's disease. Furthermore, their high blood-brain barrier penetration potential, renders them strong candidates for application as pharmaceutical agents of CNS diseases.
Patients that are allocated to the intervention group will participate in a 12 week lifestyle intervention program consisting of group exercise therapy and dietary advice combined with dietary supplementation. The group exercise therapy will be guided by trained physical therapists. Patients will participate in this part of the intervention twice a week for one hour. The exercise therapy will combine cardiorespiratory with strength training. At the start of the intervention, patients will have an appointment with a nutritional scientist or doctor in which they will receive dietary advise and dietary supplements (ProSource®) to reach the advised caloric and protein intake as composed by the Dutch Centre for Nutrition (Voedingscentrum). Dietary supplements like ProSource® are extensively tested and often used as part of general practice to patients after ICU- or hospital-discharge following critical illness.
An example embodiment of the present disclosure provides systems and methods for grading vitreous haze. A color fundoscopic photograph may be obtained. A color channel of the color fundoscopic photograph may be isolated. The color channel of the color fundoscopic photograph may be normalized. A window function may be applied to the normalized color channel to obtain a windowed color channel. A smoothing function may be applied to the windowed color channel to obtain a smoothed color channel. A high-pass filter may be applied to the smoothed color channel to obtain a filtered color channel. The filtered color channel may be transformed to a frequency domain from a spatial domain. A magnitude spectrum may be calculated. The magnitude spectrum may be integrated to determine a clarity score. A haziness score may be calculated based on the clarity score.
Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
BACKGROUND: Early-onset androgenetic alopecia (AGA) has been associated with various chronic conditions, including metabolic syndrome (MetS). Gaining a deep understanding of early-onset AGA may enable earlier intervention in individuals at high risks. This scoping review aims to explore the risk factors and etiology, associated conditions, and adverse effects on wellbeing in early-onset AGA.
METHODS: Electronic literature searches were conducted in MEDLINE, EMBASE and CENTRIAL. Eligible studies included case-control, cohort, cross-sectional, and meta-analysis studies. Selected studies needed to clearly define early-onset AGA cases or include only cases starting before the age of 40 and compare them with appropriate controls. The exclusion criteria comprised editorials, commentaries, case series, and non-systematic reviews, among others. Data extraction involved collecting study characteristics, methodologies, main outcomes, and findings. Descriptive tables were used to summarize key information and relevant variables when necessary.
RESULTS: Among the 65 eligible articles, 67.69% were case-control studies and 78.46% evaluated only male patients. "Early-onset" was defined as cases developing before the age of 30 years in 43.08% of the studies. The Hamilton-Norwood scale was the most frequently used method for evaluating the severity of alopecia in men (69.23%). Reported risk factors for early-onset AGA included a family history of AGA, cigarette smoking, unhealthy dietary habits, and a high body mass index. Early-onset AGA may also be associated with hormonal profiles, 5α-reductase enzyme activity, androgen receptor genes, and some susceptibility loci. Comorbidities investigated included MetS, cardiovascular disease, insulin resistance, dyslipidemia, and Parkinson's disease. Men with early-onset AGA may have reduced treatment efficacy with drug like rosuvastatin, metformin or lisinopril for dyslipidemia, prediabetes, or hypertension. Additionally, young men with AGA tended to suffer from psychological issues such as anxiety and low self-esteem compared to those without hair loss.
CONCLUSION: Early-onset AGA is a complex condition with various risk factors and etiology, associated comorbidities, and potential implications for treatment response and psychological health.
Method of obtaining amorphous calcium phosphate nanoparticles coated with citrate and doped with fluorine. This material presents applications in biomedicine due to its excellent biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it can be used in toothpastes, mouth rinses, chewing gum, gels and fluorine varnishes as a remineralizing agent of dentin and enamel. Part of two solutions formed by calcium chloride and sodium citrate on the one hand, and sodium monohydrogen phosphate and sodium carbonate with a fluorine compound, which are mixed at room temperature. The procedure is eco-efficient as it does not leave any acid residue; it consists of a single stage and is the first time that an amorphous calcium phosphate coated with citrate and doped with fluorine is obtained which enhances its remineralizing action. (Machine-translation by Google Translate, not legally binding)
A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether omega-3-acid ethyl esters capsules can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Omega-3-acid ethyl esters capsules should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. 

Animal Data: Omega-3-acid ethyl esters have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 grams/day based on a body surface area comparison. 

In female rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day beginning 2 weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high-dose group (5 times human systemic exposure following an oral dose of 4 grams/day based on body surface area comparison). 

In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg/kg/day from gestation day 6 through 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). 

In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day from gestation day 14 through lactation day 21, no adverse effects were seen at 2,000 mg/kg/day (5 times the human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg/kg/day (7 times the human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). 

In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg/kg/day from gestation day 7 through 19, no findings were observed in the fetuses in groups given 375 mg/kg/day (2 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).
PURPOSE: Auto plasma for the restoration of epithelial tissue or the subcutaneous tissue manufacturing method and composition with the same is provided to restore subcutaneous connective tissue and to shorten a daily life return time after the treatment as invasiveness is lessened. CONSTITUTION: An auto plasma manufacturing method for the restoration of the epithelial tissue or the subcutaneous tissue comprises a step that obtains a blood platelet rich plasma (PRP) by centrifuging blood; a step that obtains a blood platelet pour plasma (PPP) centrifuging the blood; a step in which a self trombone obtains a stabilized blood platelet poor plasma after leaving the mixture in a room temperature that mixed calcium chloride and absoluteethanol into the blood platelet poor plasma and leave in a room temperature for a long time; and a step that mixes the blood platelet rich plasma and the blood platelet poor plasma in (c) step. The sentrifugation is executed in 200-1000g. The centrifugation in the second step and the third step is executed in 1000-2000g. 3% of calcium chloride 0.05-0.5cc and a absoluteethanol 0.05-0.5cc is mixed per the blood platelet in the third step. The room temperature time is 5-30 minutes.
1,174,494. Emulsion type vaccines. NORDEN LABORATORIES, Inc. 31 May, 1967 [21 June, 1966], No. 25013/67. Heading A5B. Emulsion type vaccines are prepared by disintegrating the microorganism(s) which form the vaccine and dispersing the product in one or other of the components of a water and oil emulsion, constituents of the microorganisms serving as emulsifying agents which stabilize the emulsion. A thickener, e.g. aluminium stearate may be employed to increase the viscosity of the oil phase and a sterilant chemical e.g. methyl-, propyl- or butyl-p-hydroxy benzoate may be added so that the vaccine is selfsterilizing. Microorganisms specifically mentioned are Clostridium chauvei, Leptospira pomono, Vibrio fetus, rabies virus and C. chauvei and C. septicum in combination. A preferred oil is safflower oil.
Introduction: Cannabidiol (CBD), a phytocannabinoid isolated from cannabis plants, is an interesting candidate for studying its anti-inflammatory effects, especially in the pre-clinical and animal models. Its anti-inflammatory effects, such as reduction of edema and arthritis, have been demonstrated in animal models. However, topical CBD administration requires further evaluation of CBD dosage and efficacy in animal models and clinical settings. Methods: This in vivo study investigated the anti-inflammatory effects of topical CBD administration in an animal model. Scientific experiments, including the formalin test, writhing test, carrageenan-induced edema, histopathological examination, and detection of various proinflammatory mediators, were performed. Results: The anti-inflammatory effects in vivo after inflammation induction, represented by decreased times of paw licking, degree of paw edema, and decreased writhing response, showed that 1% of tropical CBD use had significantly comparable or better anti-inflammatory effects when compared with tropical diclofenac, an anti-inflammatory agent. Moreover, the anti-inflammatory effects were significant compared with the placebo. In addition, the histopathological examination showed that topical CBD drastically reduced leukocyte infiltration and the degree of inflammation. This study also showed that the levels of various proinflammatory mediators in the plasma of mice treated with topical CBD did not differ from those treated with diclofenac. Conclusions: The topical administration of 1% CBD gel is a potentially effective candidate for an anti-inflammatory agent. Candidate for an anti-inflammatory agent.
The invention discloses a preparation process of an uncinata spikemoss herb extract and an application thereof in an oral cleaning paste and liquid and relates to an extraction process of active ingredients of uncinata spikemoss herb and an application thereof, which is suitable for demand of industrial production, short in processing period and high in extraction efficiency. The preparation process comprises the following steps: crushing; soaking; heating; concentrating; carrying out backwashing extraction; collecting a pasty material deposited at the bottom and cooling to 15-30 DEG C; evaporating and concentrating; and finishing. In pre-treatment, a state solid-suspension transformation mode, namely powder is soaked to a suspension. An efficient backwashing extraction operation mode is then utilized. In the backwashing extraction operation, the area and time of contact between the raw material and the extracting liquid (ethanol) are effectively increased, so that the extraction effect is enhanced; the active ingredients in the material pre-treated are extracted with the highest efficiency to the maximum extent. The oral cleaning product prepared by the preparation process disclosed by the invention can be used for alleviating swelling and aching of gum and bleeding gums.
A transdermal patch having a pre-selected amount of a predetermined absorbable medicine thereon for attaching to an individual's skin. The transdermal patch includes a backing member having a predetermined size and a predetermined shape. The backing member has a first surface and a radially opposed second surface. A medicinal adhesive portion is disposed on the first surface for adhering to the individual's skin and administering the pre-selected amount of the predetermined absorbable medicine at a predetermined rate. A lining member is temporarily disposed over the first surface for providing a barrier between the medicinal adhesive portion and atmosphere until the transdermal patch is adhered to the individual's skin. A predetermined image portion is imprinted on the second surface for disguising an appearance of the transdermal patch.
Participants will perform a combination of strength and endurance training with low-to moderate-intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
OBJECTIVE: The fact that certain oral carcinoma patients experience radiotherapy failure implies that a more radioresistant and aggressive phenotype of surviving cancer cells potentially occurs during treatment. Our study aimed to establish radioresistant oral cancer cells through a fractionated irradiation protocol that mimics clinically relevant radiotherapy dosing strategies and to investigate all-round alterations in the malignant phenotype.
METHODS: Radioresistant oral carcinoma cells were generated by exposing Cal27 and Detroit 562 cells to 60 Gy radiation in 10 dose-escalating fractions and verified by cell immunofluorescence. Specific markers related to the epithelial-mesenchymal transition (EMT) process and the cancer stem cell (CSC) phenotype were assessed by Western blotting. Cell invasion and migration were evaluated using Matrigel-coated transwell and wound healing assays, respectively. Nontargeted metabolomics was used to mechanistically delineate the potential metabolic patterns linked to EMT and CSCs; the CSC phenotype was also examined by sphere formation assays and cell immunofluorescence.
RESULTS: Radioresistant oral carcinoma cell lines were successfully established and validated. These cells exhibited enhanced EMT and increase in both cell invasion and migration. These radioresistant cells further demonstrated a high metabolic profile, notably marked by lipid metabolism reprogramming and functional enrichment of ATP-binding cassette (ABC) transporters. Consistently, enhanced CSC phenotype in radioresistant cells was confirmed by elevated expression of stemness markers and increased sphere-forming capacity.
CONCLUSION: Radioresistant oral carcinoma cells subjected to fractionated radiation exhibit an augmented malignant phenotype. The metabolic characteristics linked to enhanced EMT and CSC phenotypes provide potential targets for improving radiotherapy in oral carcinoma.
Recently, it has been recognized that changes in sagittal alignment and spinopelvic mobility due to alterations of the lumbosacral spine can influence the dislocation of a hip replacement. The biggest difficulties for this problem are: a) the bibliography related to this topic has been written in English and there is confusion in its terminology; b) there is no consensus on what parameters should be used to identify, measure, and estimate the risks of dislocation occurring; c) the basic concepts that interrelate spinal disorders and prosthetic dislocation are not clearly understood; and d) spine and hip surgeons pursue different goals. The objective of this narrative review is to overcome the aforementioned difficulties by using a strategy to answer some questions: Is hip dislocation really a problem? What is the interrelationship between alterations in the pelvic spinal balance and the dislocation of a prosthesis? How is sagittal balance and lumbosacral mobility defined and how can their alterations be measured? What are their compensatory mechanisms to achieve a good functioning and how these mechanisms can be used to correctly orient the acetabulum? To document this review, we consulted the databases of PubMed, Scopus, SciELO and Google Scholar with the keywords: Spinopelvic, Total Hip Arthroplasty, Hip Dislocation, Spine-Pelvis-hip Arthroplasty. The articles that, in the author's opinion, were the most objective and/or relevant for the study of this topic were selected.